Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IKT Inhibikase Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: IKT
Price (delayed)
$2.01
Market cap
$149.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.59
Enterprise value
$76.06M
Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional
Highlights
The company's debt has shrunk by 85% YoY and by 32% QoQ
The EPS has soared by 81% YoY and by 49% from the previous quarter
The revenue has plunged by 100% YoY
Inhibikase Therapeutics's gross profit has plunged by 100% YoY
Key stats
What are the main financial stats of IKT
Market
Valuations
Earnings
Shares outstanding
74.34M
Market cap
$149.43M
Enterprise value
$76.06M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.74
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$39.57M
Net income
-$36.55M
EBIT
-$36.55M
EBITDA
-$36.52M
Free cash flow
-$19.4M
Per share
Balance sheet
Liquidity
EPS
-$0.59
EPS diluted
-$0.59
Free cash flow per share
-$0.22
Book value per share
$1.15
Revenue per share
$0
TBVPS
$1.05
Total assets
$94.28M
Total liabilities
$8.55M
Debt
$74,772
Equity
$85.73M
Working capital
$85.61M
Debt to equity
0
Current ratio
11.01
Quick ratio
10.9
Net debt/EBITDA
2.01
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-70.9%
Return on equity
-79%
Return on invested capital
-281.1%
Return on capital employed
-42.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IKT stock price
How has the Inhibikase Therapeutics stock price performed over time
Intraday
-0.99%
1 week
0.5%
1 month
1.52%
1 year
14.2%
YTD
-38.15%
QTD
-8.22%
Financial performance
How have Inhibikase Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.57M
Net income
-$36.55M
Gross margin
N/A
Net margin
N/A
The revenue has plunged by 100% YoY
Inhibikase Therapeutics's gross profit has plunged by 100% YoY
Inhibikase Therapeutics's operating income has plunged by 96% YoY and by 38% from the previous quarter
Inhibikase Therapeutics's net income has plunged by 90% YoY and by 33% from the previous quarter
Price vs fundamentals
How does IKT's price correlate with its fundamentals
Growth
What is Inhibikase Therapeutics's growth rate over time
Valuation
What is Inhibikase Therapeutics stock price valuation
P/E
N/A
P/B
1.74
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 81% YoY and by 49% from the previous quarter
The equity has declined by 10% since the previous quarter
The stock's price to book (P/B) is 3.3% less than its 5-year quarterly average of 1.8
The revenue has plunged by 100% YoY
Efficiency
How efficient is Inhibikase Therapeutics business performance
IKT's return on equity is up by 46% year-on-year and by 24% since the previous quarter
The return on assets is up by 39% year-on-year and by 21% since the previous quarter
IKT's return on invested capital is down by 14% since the previous quarter but it is up by 4.6% year-on-year
Dividends
What is IKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IKT.
Financial health
How did Inhibikase Therapeutics financials performed over time
IKT's total liabilities has surged by 129% since the previous quarter and by 99% year-on-year
Inhibikase Therapeutics's current ratio has shrunk by 58% QoQ
The company's debt is 100% lower than its equity
The debt to equity has dropped by 100% year-on-year
The company's debt has shrunk by 85% YoY and by 32% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.